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www.jcma-online.comReplyWe would like to thank Dr Li and colleagues for their
interest in our work.
We also appreciated their experience in the treatment of
ovary transitional cell carcinoma (TCC) and expected to have
chance to learn more from their research.
Primary TCC is one of the subtypes of epithelial ovarian
cancers, with an incidence of 1e2%.1 Indeed, ovarian TCC is
an uncommon type of ovarian epithelial carcinoma, but not
rare enough to for a case to have been a reported recently. The
main purpose of our report was to present the first case of
primary ovarian TCC after renal transplantation (RTx).
Urinary tract TCC after RTx is extremely high in Taiwan.
Several studies in Taiwan have demonstrated a markedly
increased frequency of urinary tract TCC in RTx recipients,
with an incidence of 4.1%.2,3 It is still unknown whether
primary ovarian TCC after RTx is caused by the same path-
ophysiological mechanism (immunosuppression, uremia, and
arsenic intoxication) as urinary tract TCC.
We also presented the whole treatment course, including
adjuvant chemotherapy, in this report.4 Dr Li et al questioned
us about our chemotherapy regimen. We have to admit that the
cisplatin-based regimen is the standard regimen for primary
ovarian TCC. Beside the chemotherapy effect, we should have
paid more attention to the transplanted kidney function.
Nephrologists and RTx patients are reluctant to receive the
possible nephrotoxicity prescription. Cisplatin-based chemo-
therapy represents the cornerstone in the treatment of many
tumors. Multi-agent regimens, such as MVAC (methotrexate,
vinblastine, doxorubicin and cisplatin) and CMV (cisplatin,
methotrexate and vinblastine) have shown results in patients
with metastatic TCC. With regard to advanced TCC in RTx
recipients, the main side-effect of cisplatin-induced nephro-
toxicity may have potential risks.5 In addition, the main side-
effects of cyslosporine are nephrotoxicity and hypertension. It
is therefore difficult for transplant physicians to conduct
a cisplatin-based chemotherapy regimen in order to treat
advanced TCC in RTx recipients who also receive cyclo-
sporine.5 Drugs such as cyclophosphamide may also enhance
the release of antidiuretic hormone, increasing the risk of
hyponatremia from inappropriate water retention, which is
a risk factor for renal tubule damage.6
The clinical course of TCC in RTx patients is aggressive.
Gemcitabine plus cisplatin has a better safety profile thanDOI of Letter to the Editor: 10.1016/j.jcma.2011.03.009.
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.09.011MVAC and may be considered the first choice for treatment of
metastatic bladder cancer. Patients unable to tolerate cisplatin
may benefit from gemcitabine plus carboplatin.7 We have
some unpublished and encouraging experience with the
combination of gemcitabine and the less nephrotoxic substi-
tute carboplatin in treating advanced urinary tract TCC after
RTx. Without prior experience and literature on treating
primary ovarian TCC in RTx patients, gemcitabine and car-
boplatin were used for this patient in the same formula as for
advanced urinary tract TCC in RTx patients. The response of
this patient seemed to be fair.
We want to elucidate the treatment course logically via this
brief report. We thank Dr Li and colleagues for raising their
queries regarding our work.
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